Warhade Achal D, More Akash, Anjankar Namrata, Dhamija Puja, Warhade Prajwal
Department of Clinical Embryology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
Senior Embryologist, Wardha Test Tube Baby Centre (WTTBC), Acharya Vinoba Bhave Rural (AVBR) Hospitals, Sawangi (Meghe), Wardha, Maharashtra, India.
J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S994-S996. doi: 10.4103/jpbs.jpbs_387_25. Epub 2025 Apr 12.
This case study reviews the use of Lymphocyte Immunotherapy (LIT) in a 28-year-old female patient who had a history of recurrent first-trimester miscarriages and failed intracytoplasmic sperm injection (ICSI) cycles. She had good ovarian reserve, normal semen analysis, and negative autoimmune tests but experienced four early miscarriages, which suggested an immune-mediated issue. LIT was chosen as a treatment option to address the possibility of immune system dysregulation contributing to pregnancy loss. LIT is the process of infusing the husband's lymphocytes to promote maternal tolerance of paternal antigens, reducing the possibility of immune foetal rejection. A received LIT was performed six weeks prior to a fresh ICSI cycle, with successful fertilization and transfer of embryos. There is evidence that positive outcomes occurred in serial ultrasounds and hormone levels at 6, 8, and 12 weeks with subsequent birth at term of a healthy baby. This case points to the possibility of using LIT as a therapeutic intervention in the treatment of unexplained recurrent miscarriage in patients who had previously failed previous assisted reproductive treatments. While the mechanism of action for LIT remains unknown, it would seem to somehow modulate the immune responses so that pregnancy results in better outcomes. This case may thus provide new evidence for LIT as a possible management strategy for those with immune causes of recurrent pregnancy loss (RPL) but warrants additional studies to optimize its use and effectivity.
本病例研究回顾了淋巴细胞免疫疗法(LIT)在一名28岁女性患者中的应用,该患者有孕早期反复流产史且胞浆内单精子注射(ICSI)周期失败。她卵巢储备良好,精液分析正常,自身免疫检测呈阴性,但经历了四次早期流产,这表明存在免疫介导问题。选择LIT作为治疗方案,以解决免疫系统失调导致妊娠丢失的可能性。LIT是输注丈夫淋巴细胞以促进母体对父源抗原的耐受性、降低免疫性胎儿排斥可能性的过程。在进行新鲜ICSI周期前六周进行了LIT,胚胎成功受精并移植。有证据表明,在6周、8周和12周的系列超声检查及激素水平检测中出现了阳性结果,随后足月产下一名健康婴儿。该病例指出,对于先前辅助生殖治疗失败的不明原因反复流产患者,使用LIT作为治疗干预措施具有可能性。虽然LIT的作用机制尚不清楚,但它似乎以某种方式调节免疫反应,从而使妊娠获得更好的结果。因此,该病例可能为LIT作为复发性妊娠丢失(RPL)免疫原因患者的一种可能管理策略提供新证据,但需要更多研究来优化其使用方法和有效性。